Background: A medical device containing xyloglucan-gelose-hibiscus-propolis (referred to hereafter as xyloglucan + gelose) acts as a mucosal barrier protector and urinary acidifier. The safety and efficacy of this device were investigated as adjuvant therapy to first-line antimicrobials for treatment of uncomplicated urinary tract infection (UTI) in adults. Patients and Methods: In this multicentre, randomised, parallel group, double-blind, phase IV study, xyloglucan + gelose (n = 20) or placebo (n = 20) were administered orally in combination with an antimicrobial agent (e.g., ciprofloxacin) for 5 days, then alone for 5 days, then beginning on Day 30 of the study for 15 days per month for 2 months. Results: Frequency of adverse events (AEs) was 5 and 45% in the xyloglucan + gelose and placebo groups respectively. All AEs were unrelated to study products. Xyloglucan + gelose reduced uroculture positivity (defined as a bacterial count ≥103 CFU/mL) from 100% of patients at baseline to 0% at Day 11, with recurrence in 3 patients (15%) by Day 76. Corresponding results with placebo were 100% uroculture positive patients at baseline reduced to 45% at Day 11, with recurrence in 14 patients (70%) by Day 76. Xyloglucan + gelose significantly reduced the frequency of urinary incontinence and urgency of micturition compared with placebo (both p < 0.05), with symptom resolution in all patients by Day 90. Conclusions: The xyloglucan + gelose medical device was safe, well tolerated, and it reduced bacteriological and symptomatic parameters in adults with uncomplicated UTI.

1.
Flores-Mireles AL, Walker JN, Caparon M, Hultgren SJ. Urinary tract infections: epidemiology, mechanisms of infection and treatment options.
Nat Rev Microbiol
. 2015 May; 13(5): 269–84.
2.
Cai T, Verze P, Brugnolli A, Tiscione D, Luciani LG, Eccher C, et al. Adherence to European Association of Urology Guidelines on prophylactic antibiotics: an important step in antimicrobial stewardship.
Eur Urol
. 2016 Feb; 69(2): 276–83.
3.
Foxman B. The epidemiology of urinary tract infection.
Nat Rev Urol
. 2010 Dec; 7(12): 653–60.
4.
Li R, Leslie SW. Cystitis. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2018.
5.
Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R, Miller LG, et al.; Infectious Diseases Society of America; European Society for Microbiology and Infectious Diseases. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases.
Clin Infect Dis
. 2011 Mar; 52(5):e103–20.
6.
Grigoryan L, Trautner BW, Gupta K. Diagnosis and management of urinary tract infections in the outpatient setting: a review.
JAMA
. 2014 Oct; 312(16): 1677–84.
7.
Wagenlehner FM, Bartoletti R, Cek M, Grabe M, Kahlmeter G, Pickard R, et al. Antibiotic stewardship: a call for action by the urologic community.
Eur Urol
. 2013 Sep; 64(3): 358–60.
8.
Jepson RG, Williams G, Craig JC. Cranberries for preventing urinary tract infections.
Cochrane Database Syst Rev
. 2012 Oct; 10: CD001321.
9.
Chisholm AH. Probiotics in preventing recurrent urinary tract infections in women: a literature review.
Urol Nurs
. 2015 Jan-Feb; 35(1): 18–21.
10.
Wagenlehner FM, Abramov-Sommariva D, Höller M, Steindl H, Naber KG. Non-antibiotic herbal therapy (BNO 1045) versus antibiotic therapy (fosfomycin trometamol) for the treatment of acute lower uncomplicated urinary tract infections in women: a double-blind, parallel-group, randomized, multicentre, non-inferiority phase III trial.
Urol Int
. 2018; 101(3): 327–36.
11.
Lopetuso LR, Scaldaferri F, Bruno G, Petito V, Franceschi F, Gasbarrini A. The therapeutic management of gut barrier leaking: the emerging role for mucosal barrier protectors.
Eur Rev Med Pharmacol Sci
. 2015; 19(6): 1068–76.
12.
Pleșea Condratovici C, Bacarea V, Piqué N. Xyloglucan for the treatment of acute gastroenteritis in children: results of a randomized, controlled, clinical trial.
Gastroenterol Res Pract
. 2016; 2016: 6874207.
13.
Gnessi L, Bacarea V, Marusteri M, Piqué N. Xyloglucan for the treatment of acute diarrhea: results of a randomized, controlled, open-label, parallel group, multicentre, national clinical trial.
BMC Gastroenterol
. 2015 Oct; 15(1): 153.
14.
Çağan E, Ceylan S, Mengi Ş, Çağan HH. Evaluation of gelatin tannate against symptoms of acute diarrhea in pediatric patients.
Med Sci Monit
. 2017 Apr; 23: 2029–34.
15.
Kara SS, Volkan B, Erten İ. The therapeutic effect of gelatin tannate in acute diarrhea in children.
Turk J Pediatr
. 2017; 59(5): 531–6.
16.
Mennini M, Tolone C, Frassanito A, Midulla F, Cucchiara S, Aloi M. Gelatin tannate for acute childhood gastroenteritis: a randomized, single-blind controlled trial.
Paediatr Drugs
. 2017 Apr; 19(2): 131–7.
17.
de Servi B, Ranzini F, Piqué N. Effect of Utipro(®) (containing gelatin-xyloglucan) against Escherichia coli invasion of intestinal epithelial cells: results of an in vitro study.
Future Microbiol
. 2016 May; 11(5): 651–8.
18.
Olier M, Sekkal S, Harkat C, Eutamene H, Theodorou V. Evaluation of reticulated gelatin-hibiscus-propolis against intestinal commensal species commonly associated with urinary tract infections.
Future Microbiol
. 2017 May; 12(6): 505–13.
19.
Fraile B, Alcover J, Royuela M, Rodríguez D, Chaves C, Palacios R, et al. Xyloglucan, hibiscus and propolis for the prevention of urinary tract infections: results of in vitro studies.
Future Microbiol
. 2017 Jun; 12(8): 721–31.
20.
Esposito E, Campolo M, Casili G, Lanza M, Franco D, Filippone A, et al. Protective effects of xyloglucan in association with the polysaccharide gelose in an experimental model of gastroenteritis and urinary tract infections.
Int J Mol Sci
. 2018 Jun; 19(7):E1844.
21.
Kranz J, Schmidt S, Lebert C, Schneidewind L, Mandraka F, Kunze M, et al. The 2017 update of the German clinical guideline on epidemiology, diagnostics, therapy, prevention, and management of uncomplicated urinary tract infections in adult patients: Part 1.
Urol Int
. 2018; 100(3): 263–70.
22.
Kranz J, Schmidt S, Lebert C, Schneidewind L, Mandraka F, Kunze M, et al. The 2017 update of the German clinical guideline on epidemiology, diagnostics, therapy, prevention, and management of uncomplicated urinary tract infections in adult patients. Part II: therapy and prevention.
Urol Int
. 2018; 100(3): 271–8.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.